Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa

  • Antimicrob Agents Chemother. 2023 May 31;e0033923. doi: 10.1128/aac.00339-23.
Christophe Le Terrier  1  2 ,  Patrice Nordmann  1  3  4 ,  Charlotte Freret  1 ,  Marion Seigneur  1 ,  Laurent Poirel  1  3
Affiliations
  • 1. Emerging Antibiotic Resistance Unit, Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.
  • 2. Division of Intensive care unit, University hospitals of Geneva, Geneva, Switzerland.
  • 3. Swiss National Reference Center for Emerging Antibiotic Resistance, Fribourg, Switzerland.
  • 4. University of Lausanne and University hospital Center, Lausanne, Switzerland.
PMID: 37255469 DOI: 10.1128/aac.00339-23
Abstract

The impact of broad-spectrum β-lactamases on the susceptibility to novel β-lactamase/β-lactamase inhibitor combinations was evaluated both in Pseudomonas aeruginosa and Escherichia coli using isogenic backgrounds. Cefepime-zidebactam displayed low MICs, mainly due to the significant intrinsic Antibacterial activity of zidebactam. Cefepime-taniborbactam showed excellent activity against recombinant E. coli strains, including Metallo-β-lactamase producers, whereas aztreonam-avibactam remained the best therapeutic option against class B β-lactamase-producing P. aeruginosa.

Keywords
avibactam; enmetazobactam; nacubactam; relebactam; susceptibility testing; taniborbactam; vaborbactam; zidebactam; β-lactamase.
Products